NCT02658825 - A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Healthy

Interventions

DRUG

JNJ-63623872 2400 milligram (mg)

Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.

DRUG

JNJ-63623872 3000 mg

Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.

DRUG

JNJ-63623872

Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.

DRUG

Moxifloxacin

Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.

DRUG

Placebo (Matching with JNJ-63623872 2400 mg)

Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.

DRUG

Placebo (Matching with JNJ-63623872 3000 mg)

Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.

DRUG

Placebo (Matching with JNJ-63623872 Dose)

Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.

DRUG

Placebo (Matching with Moxifloxacin)

Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.

Trial Locations (1)

Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY